Please wait while the formulary information is being retrieved.
POMBILITI (cipaglucosidase alfa-atga)
- Pompe disease
105 mg intravenous solution
- Infuse 20 mg/kg over approximately 4 hour(s) by intravenous route every 2 weeks
Default screening record
- Infuse 20 mg/kg over approximately 4 hour(s) by intravenous route every 2 weeks
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactation
- Pregnancy
Contraindicated
- Acute respiratory failure
- Chronic heart failure
Severe
Moderate
- None
POMBILITI (cipaglucosidase alfa-atga)
- Pompe disease
- None
- Acute abdominal pain
- Diarrhea
- Fatigue
- Fever
- Headache disorder
- Nausea
More Frequent
Severe
Less Severe
- Anaphylaxis
- Hypersensitivity drug reaction
- Paradoxical bronchospasm
- Pharyngeal edema
- Tongue swelling
- Chills
- Dizziness
- Dysgeusia
- Dyspnea
- Flushing
- Muscle spasm
- Pruritus of skin
- Skin rash
- Tachycardia
- Urticaria
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- Arthralgia
- Constipation
- Dyspepsia
- Flank pain
- General weakness
- Hypertension
- Malaise
- Myalgia
- Paresthesia
- Thrombocytopenic disorder
- Tremor
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Cipaglucosidase alfa-atga
Safety and effectiveness have not been established in pediatric patients
- 1 Day – 18 Years
- Safety and effectiveness have not been established in pediatric patients
Cipaglucosidase Alfa-atga
- Severity Level:
1
- Additional Notes: Contraindicated during pregnancy
Contraindicated
Cipaglucosidase Alfa-atga
Mfr recommends avoid breastfeeding
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfr recommends avoid breastfeeding |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Infusion reactions or serious (sometimes fatal) allergic reactions may happen while you are receiving cipaglucosidase alfa and for a short time after. Your doctor may prescribe other medications (such as a fever reducer, antihistamines, corticosteroids) for you to take to help decrease these side effects. Carefully follow your doctor's directions for all of your medications.<br /><br />Get medical help right away if you notice any signs of a serious allergic reaction, such as rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing, chills, or flushing. Your infusion may be slowed down or stopped depending on your symptoms. Before starting treatment with this medication, tell your doctor if you have a history of heart problems (such as heart failure), breathing problems (such as fluid in the lungs), or swelling.<br /><br />These problems may get worse during the infusion. Your doctor or nurse may monitor you for longer periods after your infusion.
| Lysosomal alpha-1,4-glucosidase deficiency | |
| E74.02 | Pompe disease |
| 0-9 | A-Z |
|---|---|
| E74.02 | Pompe disease |
Formulary Reference Tool